Bill Gates is worth $50 billion less than thought — and now trails his former assistant in net worth
The change lowered his net worth by 30%, sending him seven places down Bloomberg's rich list.
Gates now sits in 12th place, behind his former assistant, Steve Ballmer, in fifth.
Bill Gates lost about $52 billion or 30% of his wealth on Thursday. But don't feel bad — his net worth was simply recalculated to reflect the Microsoft cofounder's charitable giving.
The recalculation shrank Gates' fortune from over $175 billion to $124 billion, sending him from fifth place to 12th on the Bloomberg Billionaires Index. His former assistant and successor as Microsoft's CEO, Steve Ballmer, replaced him in the fifth spot with a $172 billion net worth as of Thursday's close.
Gates also trails Alphabet cofounders Larry Page and Sergey Brin, Nvidia CEO Jensen Huang, and longtime friend and Berkshire Hathaway CEO Warren Buffett in the rankings.
Bloomberg says that it lowered the appreciation rates used in calculating his wealth to "better reflect Gates' outside charitable giving and the wealth estimate" that Gates provided in a blog post in May.
In that blog, Gates pegged his fortune at $108 billion and pledged to give away virtually all his money through the Gates Foundation over the next 20 years. He estimated the organization would spend more than $200 billion before closing at the end of 2045.
According to the Gates Foundation website, Gates and his ex-wife, Melinda French Gates, have gifted a total of $60 billion to the organization as of December's close, and Buffett has donated $43 billion.
Gates owns around 1% of Microsoft and has received upward of $60 billion in stocks and dividends from the company, according to his Bloomberg page. Most of his fortune is now housed within Cascade Investment, a holding company that invests in assets from real estate and energy to private and public companies.
It's striking that Ballmer is now richer than Gates, given that employees are usually worth much less than successful founders.
He's an exception in part because, when he joined Microsoft in 1980 as an assistant to the president, he agreed to a $50,000 base salary plus 10% of the profit growth he generated, but his compensation became so high that the company offered a sizable equity stake instead.
Ballmer succeeded Gates as CEO in 2000 and stepped down in 2014 with a 4% stake in Microsoft. He now owns the Los Angeles Clippers.
Microsoft stock has soared more than 10-fold over the past decade to nearly $500 a share, making it the world's second-most valuable company, after Nvidia, with a $3.7 trillion market cap.
Ballmer recently told the "Acquired" podcast that Buffett's late business partner, Charlie Munger, asked him publicly why he held on to his Microsoft stock while the company's two cofounders, Gates and Paul Allen, diversified their investments much more.
"Steve, I'm wondering why you held onto your Microsoft stock when your partners over there didn't," Ballmer recalled the famously frank Munger saying. "I know you're not that smart."
"No, Charlie, but I'm that loyal," Ballmer replied.
Read the original article on Business Insider
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
21 minutes ago
- Associated Press
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. ('Sarepta' or the 'Company') (NASDAQ: SRPT) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) ELEVIDYS posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (iv) as a result of the foregoing, Defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. On March 18, 2025, Sarepta issued a safety update on ELEVIDYS announcing that a patient had died following treatment with ELEVIDYS. On this news, Sarepta's stock price fell $27.81 per share, or 27.44%, to close at $73.54 per share on March 18, 2025. Then, on April 4, 2025, Sarepta disclosed that European Union member country authorities had requested that the independent data monitoring committee meet to review death announced on March 18, 2025. Sarepta simultaneously halted recruitment and dosing in some of the ELEVIDYS clinical studies. On this news, Sarepta's stock price fell $4.18 per share, or 7.13%, to close at $54.43 per share on April 4, 2025. Next, on June 15, 2025, Sarepta disclosed a second patient had died of acute liver failure following treatment with ELEVIDYS. The Company announced it was suspending shipments of ELEVIDYS for non-ambulatory patients while Sarepta took time to evaluate trial regimens and discussed findings with regulatory authorities. Sarepta also revealed that it was pausing dosing in one of its ELEVIDYS clinical studies. On this news, Sarepta's stock price fell $15.24 per share, or 42.12%, to close at $20.91 per share on June 15, 2025. Finally, on June 24, 2025, the United States Food and Drug Administration ('FDA') issued a Safety Communication announcing it had received reports of two deaths and was investigating the risk of acute liver failure with serious outcomes following treatment with ELEVIDYS. The communication noted that the FDA was evaluating the need for further regulatory action. On this news, Sarepta's stock price fell $1.52 per share, or 8.01%, to close at $17.46 per share on June 25, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Sarepta's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Sarepta Therapeutics class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at
Yahoo
28 minutes ago
- Yahoo
What to Expect From Bitcoin and Crypto Markets in the 2nd Half of 2025
Bitcoin treasury companies are becoming a dominant force in the crypto market, a trend that analysts expect to continue in the second half of 2025. More spot crypto ETFs and crypto-related IPOs are also right around the corner. Ether has lagged behind bitcoin and many smaller crypto assets over the past few years, but some experts say it's not time to give up on the world's second-largest crypto asset just been a tremendous year so far for bitcoin and the crypto market. Cryptocurrencies have gained greater acceptance in Washington, with President Donald Trump establishing a strategic bitcoin reserve and the Senate passing the GENIUS Act. They've also found favor with traditional finance; spot bitcoin exchange-traded fund net inflows in 2025 have totaled $14.4 billion through July 3, according to data from Farside Investors. Bitcoin (BTCUSD) has gained about 15% since the start of year, outpacing the S&P 500's rise of 7%. It isn't far from the all-time high of near $112,000 set in May, edging closer to the bullish year-end targets analysts set at the start of the year. Here's what crypto investors will be watching for in the second half of the year. So-called bitcoin treasury companies have been the talk of the town in 2025. A bitcoin treasury company is a business that holds a substantial portion of its reserve assets in bitcoin, often as an inflation hedge or in anticipation of bitcoin's development as a global, apolitical reserve asset. Some companies, like Michael Saylor's Strategy (MSTR), take it a step further by issuing shares or debt to accumulate bitcoin. Strategy (formerly MicroStrategy) has been at this for years, but there are several new players entering the arena, including Metaplanet and Twenty One. There are now an estimated 135 public companies that hold bitcoin as a reserve asset. "The latter half of 2025 will mark a pivotal moment for bitcoin's adoption as a treasury asset, driven by a convergence of global market trends, shifting corporate strategies, and institutional validation,' Stephen Cole, who is the co-founder and CEO of bitcoin treasury solution provider Castle, told Investopedia. "We're already seeing bitcoin treasury companies emerge in every major global capital market and [I] expect that trend to continue," he said. Cole expects larger companies, including well-known tech giants, to begin establishing bitcoin positions and defining their allocation strategies by the end of the year. 'For (small and medium sized businesses) and large corporations alike, the question of whether to acquire bitcoin is quickly going from if to when,' Cole added. Some have wondered if bitcoin treasury companies will sap demand for smaller, more volatile altcoins. 'Demand for altcoins has historically stemmed from two main sources: (1) beta exposure to bitcoin, and (2) differentiated use cases that bitcoin's blockchain doesn't fulfill,' David Lawant, Head of Research at FalconX, told Investopedia. 'What we're seeing now is that bitcoin treasury companies and broader access to instruments like options can meet that first demand more efficiently and with less friction.' However, Lawant says bitcoin treasuries only satisfy some of the criteria that drive demand for altcoins. He also cautioned that 'the cycle is likely far from over,' and in his view, there is still time for certain types of alternative crypto assets to shine. 'Altcoins with a strong and distinct fundamental value proposition still have plenty of room to perform,' said Lawant. 'Regulatory shifts such as the crypto market structure bill and a more permissive stance toward decentralized finance (DeFi) experimentation could unlock powerful new trends.' Of course, bitcoin treasury companies aren't the only way to gain exposure to bitcoin and other crypto assets via public markets. Spot ETFs for bitcoin and ether already exist, and according to Bloomberg analyst James Seyffart, similar products could be on the way for other digital assets. Tweaks to existing ETFs, such as in-kind redemption and staking, are also likely. 'I think we will see the vast majority, if not all, of the currently filed 19b-4s obtain approval by the end of the year,' Seyffart told Investopedia. 'That includes in-kind [redemptions] and staking and something like 10 individual assets [that have] attempted to get an ETF.' Additionally, the undeniable success of the IPO for stablecoin issuer Circle (CRCL) has not gone unnoticed. Galaxy (GLXY) and eToro (ETOR), which are both heavily involved in the crypto market, also debuted earlier this year. According to Nate Geraci, President of The ETF Store, there could be more IPOs on the way from the likes of crypto exchanges Gemini and Kraken, and blockchain technology companies Consensys and Ripple, among others. Finally, ether (ETHUSD), the native cryptocurrency of the Ethereum blockchain and long the second-largest crypto asset behind bitcoin, may also be at a critical point in its history. It has underperformed both bitcoin and some of its smaller competitors, such as Binance Smart Chain and Solana, in recent years. A recent report from a group of Ethereum proponents gained attention for comparing ether to digital oil. Still, some investors doubt that the use of Ethereum's tech by the likes of Coinbase Global (COIN) and stablecoin-issuers will necessarily accrue value to the ether asset itself over the long term. That said, Lawant believes there are still plenty of reasons to not count out ether quite yet. 'There have been clear signs over the past few months that sentiment is shifting in the Ethereum ecosystem,' said Lawant. 'Ethereum also benefits from being more closely tied to traditional capital markets, which is a key price driver in today's environment. That's evident in its active CME futures market and the launch of spot ETFs." Ether "also remains underowned by many institutional investors," says Lawant. Analysts say the addition of staking to spot ether ETFs could help improve institutional adoption. "If the current developments play out as expected, there's meaningful room for a catch-up.' Ether is down about 85% relative to bitcoin since hitting an all-time high of 0.1475 ether per bitcoin roughly eight years ago, according to data from CoinGecko. Read the original article on Investopedia Sign in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
How To Put $100 In Your Retirement Fund Each Month With AGNC Investment Stock
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. AGNC Investment Corp. (NASDAQ:AGNC) is a real estate investment trust that primarily invests in Agency residential mortgage-backed securities. The 52-week range of AGNC Investment stock price was $7.85 to $10.85. AGNC Investment's dividend yield is 15.40%. It paid $1.44 per share in dividends during the last 12 months. Don't Miss: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. . GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — The company on April 21 announced its Q1 2025 earnings, posting net spread and dollar roll income of $0.44, beating the consensus estimate of $0.40, as reported by Benzinga. 'Following the April tariff announcement, financial market volatility increased substantially, and Agency MBS spreads to benchmark rates widened. With our conservative leverage profile and ample liquidity at quarter end, AGNC was well-positioned for this instability. Although the widening of Agency MBS spreads drove a modest decline in our tangible book value, our anticipated portfolio returns have increased commensurately with today's wider spread environment. Moreover, at current valuation levels, we believe Agency MBS offer investors a compelling return opportunity on both a levered and unlevered basis,' said CEO Peter Federico. Check out this article by Benzinga for five analysts' insights on AGNC Investment. Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — If you want to make $100 per month — $1,200 annually — from AGNC Investment dividends, your investment value needs to be approximately $7,792, which is around 834 shares at $9.34 each. Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (15.40% in this case). So, $1,200 / 0.154 = $7,792 to generate an income of $100 per month. You can calculate the dividend yield by dividing the annual dividend payments by the current price of the stock. The dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40). In summary, income-focused investors may find AGNC Investment stock an attractive option for making a steady income of $100 per month by owning 834 shares of stock. Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Image: Shutterstock This article How To Put $100 In Your Retirement Fund Each Month With AGNC Investment Stock originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
